LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Momelotinib | 1.11 | uM | LJP5 | 2 | P09 | 72 | hr | 1476 | 2691 | 3694 | 0.7285 | 0.5476 |
| SK-BR-3 | Momelotinib | 1.11 | uM | LJP5 | 3 | P09 | 72 | hr | 1476 | 2651 | 3694 | 0.7176 | 0.5296 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP5 | 1 | D03 | 72 | hr | 1476 | 2991 | 3694 | 0.8097 | 0.6829 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP5 | 2 | D03 | 72 | hr | 1476 | 3003 | 3694 | 0.8129 | 0.6883 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP5 | 3 | D03 | 72 | hr | 1476 | 2984 | 3694 | 0.8078 | 0.6798 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP6 | 1 | I03 | 72 | hr | 1476 | 3209 | 3694 | 0.8687 | 0.7813 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP6 | 2 | I03 | 72 | hr | 1476 | 3258 | 3694 | 0.8820 | 0.8033 |
| SK-BR-3 | Dasatinib | 1.11 | uM | LJP6 | 3 | I03 | 72 | hr | 1476 | 3218 | 3694 | 0.8711 | 0.7853 |
| SK-BR-3 | Dovitinib | 1.11 | uM | LJP5 | 1 | E21 | 72 | hr | 1476 | 2647 | 3694 | 0.7166 | 0.5278 |
| SK-BR-3 | Dovitinib | 1.11 | uM | LJP5 | 2 | E21 | 72 | hr | 1476 | 2548 | 3694 | 0.6898 | 0.4831 |
| SK-BR-3 | Dovitinib | 1.11 | uM | LJP5 | 3 | E21 | 72 | hr | 1476 | 2518 | 3694 | 0.6816 | 0.4696 |
| SK-BR-3 | Enzastaurin | 1.11 | uM | LJP5 | 1 | D15 | 72 | hr | 1476 | 3944 | 3694 | 1.0677 | 1.1127 |
| SK-BR-3 | Enzastaurin | 1.11 | uM | LJP5 | 2 | D15 | 72 | hr | 1476 | 4049 | 3694 | 1.0961 | 1.1601 |
| SK-BR-3 | Enzastaurin | 1.11 | uM | LJP5 | 3 | D15 | 72 | hr | 1476 | 4066 | 3694 | 1.1007 | 1.1677 |
| SK-BR-3 | Erlotinib | 1.11 | uM | LJP5 | 1 | M21 | 72 | hr | 1476 | 3445 | 3694 | 0.9326 | 0.8877 |
| SK-BR-3 | Erlotinib | 1.11 | uM | LJP5 | 2 | M21 | 72 | hr | 1476 | 3237 | 3694 | 0.8763 | 0.7939 |
| SK-BR-3 | Erlotinib | 1.11 | uM | LJP5 | 3 | M21 | 72 | hr | 1476 | 3337 | 3694 | 0.9033 | 0.8390 |
| SK-BR-3 | Foretinib | 1.11 | uM | LJP5 | 1 | H09 | 72 | hr | 1476 | 1443 | 3694 | 0.3906 | -0.0152 |
| SK-BR-3 | Foretinib | 1.11 | uM | LJP5 | 2 | H09 | 72 | hr | 1476 | 1376 | 3694 | 0.3725 | -0.0454 |
| SK-BR-3 | Foretinib | 1.11 | uM | LJP5 | 3 | H09 | 72 | hr | 1476 | 1311 | 3694 | 0.3549 | -0.0747 |
| SK-BR-3 | R406 | 1.11 | uM | LJP6 | 1 | C15 | 72 | hr | 1476 | 4281 | 3694 | 1.1589 | 1.2647 |
| SK-BR-3 | R406 | 1.11 | uM | LJP6 | 2 | C15 | 72 | hr | 1476 | 3895 | 3694 | 1.0544 | 1.0906 |
| SK-BR-3 | R406 | 1.11 | uM | LJP6 | 3 | C15 | 72 | hr | 1476 | 4443 | 3694 | 1.2027 | 1.3378 |
| SK-BR-3 | Pictilisib | 1.11 | uM | LJP6 | 1 | D21 | 72 | hr | 1476 | 1607 | 3694 | 0.4350 | 0.0588 |
| SK-BR-3 | Pictilisib | 1.11 | uM | LJP6 | 2 | D21 | 72 | hr | 1476 | 1836 | 3694 | 0.4970 | 0.1620 |